On December 16, 2025, the FDA approved a new biologic for severe persistent eosinophilic asthma called Exdensur (depemokimab). This is an anti-IL5 monoclonal antibody that reduces eosinophilic inflammation, similar to other anti-IL5 biologics like Fasenra (benralizumab) and Nucala (mepolizumab). What makes Exdensur (depemokimab) unique is its long half-life, which makes it an ultra-long-acting biologic that only requires an injection once every 6 months. We now have several different biologic options for patients with uncontrolled, moderate to severe persistent asthma. If your asthma is uncontrolled, we encourage you to schedule a visit with one of our board-certified allergists to discuss treatment options.